	US 12,037,407 B2
	Immune cells having co-expressed shRNAS and logic gate systems
Jasper Williams, San Francisco, CA (US); Michelle Nguyen, San Francisco, CA (US); Anzhi Yao, San Francisco, CA (US); Stephen Santoro, Daly City, CA (US); Aaron Cooper, Berkeley, CA (US); John Gagnon, San Francisco, CA (US); Adam Litterman, San Francisco, CA (US); Omar Khan, Philadelphia, PA (US); Natalie Bezman, Foster City, CA (US); Katherine Harris, Newark, CA (US); Harbani Kaur Malik Chaudhry, Oakland, CA (US); and Nicole Allen, Fremont, CA (US)
Assigned to Arsenal Biosciences, Inc., South San Francisco, CA (US)
Filed by Arsenal Biosciences, Inc., South San Francisco, CA (US)
Filed on May 3, 2023, as Appl. No. 18/311,856.
Application 18/311,856 is a continuation of application No. PCT/US2022/078158, filed on Oct. 14, 2022.
Claims priority of provisional application 63/303,422, filed on Jan. 26, 2022.
Claims priority of provisional application 63/255,889, filed on Oct. 14, 2021.
Claims priority of provisional application 63/255,887, filed on Oct. 14, 2021.
Claims priority of provisional application 63/255,891, filed on Oct. 14, 2021.
Prior Publication US 2023/0340139 A1, Oct. 26, 2023
Int. Cl. C07K 16/28 (2006.01); A61P 35/00 (2006.01)

CPC C07K 16/2878 (2013.01) [A61P 35/00 (2018.01); C07K 16/2896 (2013.01); C07K 2317/565 (2013.01); C07K 2317/73 (2013.01); C07K 2317/76 (2013.01)]

71 Claims

1. One or more recombinant nucleic acid molecule(s), wherein the one or more recombinant nucleic acid molecules(s) encode:

a. a first chimeric polypeptide comprising a priming receptor comprising a first extracellular antigen-binding domain that specifically binds to Alkaline Phosphatase, Germ Cell (ALPG/P), wherein the first extracellular antigen-binding domain comprises a variable heavy (VH) chain sequence comprising three heavy chain CDR sequences, CDR-H1, CDR-H2, and CDR-H3, and a variable light (VL) chain sequence comprising three light chain CDR sequences, CDR-L1, CDR-L2, and CDR-L3, wherein:

i. CDR-H1 comprises the sequence set forth in SEQ ID NO: 1,

ii. CDR-H2 comprises the sequence set forth in SEQ ID NO: 2,

iii. CDR-H3 comprises the sequence set forth in SEQ ID NO: 3,

iv. CDR-L1 comprises the sequence set forth in SEQ ID NO: 4,

v. CDR-L2 comprises the sequence set forth in SEQ ID NO: 5, and

vi. CDR-L3 comprises the sequence set forth in SEQ ID NO: 6; and

b. a second chimeric polypeptide comprising a chimeric antigen receptor (CAR) comprising a second extracellular antigen-binding domain that specifically binds to mesothelin (MSLN), wherein the second extracellular antigen-binding domain comprises a VHH comprising a variable heavy (VH) chain sequence comprising three heavy chain CDR sequences, CDR-H1, CDR-H2, and CDR-H3, wherein:

i. CDR-H1 comprises the sequence set forth in SEQ ID NO: 14,

ii. CDR-H2 comprises the sequence set forth in SEQ ID NO: 15, and

iii. CDR-H3 comprises the sequence set forth in SEQ ID NO: 16.